These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 2505272

  • 21. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
    Reitsma DJ, Guinan P, Lamm DL, Khanna OP, Brosma SA, DeKernion JB, Williams RD, Sipmson G, Hanna MG.
    Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
    [No Abstract] [Full Text] [Related]

  • 22. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS.
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [Abstract] [Full Text] [Related]

  • 23. Treatment of superficial carcinoma of the bladder.
    Paulson DF.
    Prog Clin Biol Res; 1984 Mar; 162B():193-209. PubMed ID: 6209720
    [No Abstract] [Full Text] [Related]

  • 24. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA, Whitmore WF, Oettgen HF.
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [Abstract] [Full Text] [Related]

  • 25. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S.
    Prog Clin Biol Res; 1989 Jan; 310():193-205. PubMed ID: 2771993
    [No Abstract] [Full Text] [Related]

  • 26. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 27. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Aug; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 28. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 29. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C, Minocchi L, Arecchi S, Nicolucci D, Porcelli C, D'orazi V, Greco L, Stio F, Martino G, Messinetti S.
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract] [Full Text] [Related]

  • 30. Superficial bladder disease: case studies and therapeutic advances.
    Soloway MS, Droller MJ, Flanigan RC, Nseyo UO.
    Urology; 1992 Dec; 40(6 Suppl):11-22. PubMed ID: 1466118
    [No Abstract] [Full Text] [Related]

  • 31. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
    Lamm DL.
    Cancer Surv; 1998 Dec; 31():99-108. PubMed ID: 15281319
    [Abstract] [Full Text] [Related]

  • 32. [Results of BCG in the treatment of pTa and pT1 bladder tumors. Evaluation of a long protocol using 75 mg of Pasteur strain BCG].
    Ayed M, Ben Hassine L, Ben Slama R, Chelbi N, Ghozzi S, Drissi H, Jemni M, Chebil M.
    Prog Urol; 1998 Apr; 8(2):206-10. PubMed ID: 9615929
    [Abstract] [Full Text] [Related]

  • 33. [Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
    Pouya M, Opsomer RJ, Wese FX, Saleh M, Donnay M, Van Cangh PJ.
    Acta Urol Belg; 1996 Mar; 64(1):47-53. PubMed ID: 8659335
    [Abstract] [Full Text] [Related]

  • 34. BCG therapy of superficial bladder tumors.
    Herr HW.
    Prog Clin Biol Res; 1989 Mar; 303():369-74. PubMed ID: 2674999
    [No Abstract] [Full Text] [Related]

  • 35. [Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin].
    Ackermann D, Schnyder M, Bandelier D, Studer UE.
    J Urol (Paris); 1986 Mar; 92(1):33-8. PubMed ID: 3722851
    [Abstract] [Full Text] [Related]

  • 36. Intravesical mitomycin C and superficial bladder tumors.
    Biserte J, Rigot JM, Mauroy B, Mazeman E.
    Prog Clin Biol Res; 1989 Mar; 303():411-5. PubMed ID: 2506555
    [No Abstract] [Full Text] [Related]

  • 37. [Place of endovesical "BCG Therapy" in superficial tumors of the bladder].
    Zerbib M.
    J Urol (Paris); 1995 Mar; 101(2):59-63. PubMed ID: 8522855
    [Abstract] [Full Text] [Related]

  • 38. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
    Steg A, Belas M, Leleu C, Boccon-Gibod L.
    Prog Clin Biol Res; 1989 Mar; 303():375-81. PubMed ID: 2780654
    [No Abstract] [Full Text] [Related]

  • 39. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A, Belas M, Leleu C, Boccon-Gibod L.
    Prog Clin Biol Res; 1989 Mar; 310():153-60. PubMed ID: 2771990
    [No Abstract] [Full Text] [Related]

  • 40. Low-dose BCG-Pasteur strain in the treatment of superficial bladder cancer: preliminary results.
    Pagano F, Bassi P, Milani C, Meneghini A, Tuccitto G, Garbeglio A, Guazzieri S.
    Prog Clin Biol Res; 1989 Mar; 310():253-61. PubMed ID: 2672015
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.